We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+14.3%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$136M
AUM Growth
+$32.4M
Cap. Flow
-$1.27M
Cap. Flow %
-0.94%
Top 10 Hldgs %
79.4%
Holding
37
New
10
Increased
5
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$4.33M
2
BPMC
Blueprint Medicines
BPMC
+$2.25M
3
OPK icon
Opko Health
OPK
+$2.19M
4
WGS icon
GeneDx Holdings
WGS
+$778K
5
SGRY icon
Surgery Partners
SGRY
+$572K

Top Sells

Rank Stock Value
1
DMTK
DermTech, Inc. Common Stock
DMTK
+$2.54M
2
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$2.25M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.01M
4
AGEN
Agenus
AGEN
+$1.54M
5
SWTX
SpringWorks Therapeutics
SWTX
+$1.12M

Sector Composition

Rank Sector Weight
1 Healthcare 76.83%
2 Miscellaneous 22.29%
3 Energy 0.46%
4 Technology 0.41%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
1
Pacific Biosciences
PACB
$426M
$26.8M 19.75%
2,015,495
– –
QDEL icon
2
QuidelOrtho
QDEL
$728M
$20.3M 14.99%
245,495
+49,487
+25% +$4.33M
BHVN icon
3
Biohaven
BHVN
$2.06B
$14.3M 10.54%
597,773
-37,703
-6% -$649K
OPK icon
4
Opko Health
OPK
$1.25B
$9.21M 6.78%
4,242,465
+1,399,300
+49% +$2.19M
SGRY icon
5
CALL
Surgery Partners
SGRY
$1.73B
$7.87M 5.8%
+175,000
New +$6.68M
PACB icon
6
CALL
Pacific Biosciences
PACB
$426M
$6.85M 5.05%
+515,100
New +$6.26M
QDEL icon
7
CALL
QuidelOrtho
QDEL
$728M
$6.81M 5.02%
82,200
+32,800
+66% +$2.87M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.51M 4.06%
152,600
-48,800
-24% -$2.01M
WGS icon
9
GeneDx Holdings
WGS
$3.02B
$5.16M 3.8%
865,849
+98,332
+13% +$778K
AGEN
10
Agenus
AGEN
$355M
$4.89M 3.6%
152,823
-48,180
-24% -$1.54M
BPMC
11
CALL
DELISTED
Blueprint Medicines
BPMC
$4.08M 3%
+64,500
New +$3.51M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.22B
$3.91M 2.88%
555,522
– –
FORA
13
DELISTED
Forian
FORA
$3.34M 2.46%
1,364,329
– –
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$2.62M 1.93%
+41,377
New +$2.25M
ARDX icon
15
Ardelyx
ARDX
$883M
$2.37M 1.75%
699,700
-10,000
-1% -$41K
IMMP
16
Immutep
IMMP
$42.4M
$1.89M 1.39%
894,391
-456,411
-34% -$854K
MRTX
17
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.81M 1.33%
+50,000
New +$2.06M
AXDX
18
DELISTED
Accelerate Diagnostics
AXDX
$1.22M 0.9%
151,065
– –
BHVN icon
19
CALL
Biohaven
BHVN
$2.06B
$1.16M 0.86%
+48,600
New +$837K
OMGA
20
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$1.11M 0.81%
197,449
-136,387
-41% -$1.07M
KYNB
21
CALL
Kyntra Bio
KYNB
$28.7M
$748K 0.55%
+11,080
New +$4.58M
BIIB icon
22
Biogen
BIIB
$31.8B
$687K 0.51%
2,412
– –
SGRY icon
23
Surgery Partners
SGRY
$1.73B
$675K 0.5%
+15,000
New +$572K
VTNR
24
DELISTED
Vertex Energy, Inc
VTNR
$628K 0.46%
100,400
+50,400
+101% +$355K
PLTR icon
25
Palantir
PLTR
$427B
$563K 0.41%
+36,700
New +$417K
1
2

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
AIL
Atomic Invest LLC New York $178M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
CNFG
Creegan & Nassoura Financial Group Portsmouth, New Hampshire $154M AUM 17.18% 1-Year Est. Return
VA
Verus Advisory Seattle, Washington $153M AUM

Oracle Investment Management's Q2 2023 Portfolio in Review

As of Q2 2023, Oracle Investment Management held 37 positions worth $136M, up 31% from $103M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Oracle Investment Management's Q2 2023 filing shows 10 new, 5 increased, 9 reduced and 8 closed positions. Its largest new stake was Blueprint Medicines: 41,377 shares worth $2.62M. The largest sale was DermTech, Inc. Common Stock, an estimated $2.54M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Energy.

  • Oracle Investment Management's largest Q2 2023 buy was Blueprint Medicines: 41,377 shares worth $2.62M.
  • Oracle Investment Management added most to QuidelOrtho in Q2 2023, an estimated $4.33M increase.
  • Oracle Investment Management's biggest Q2 2023 reduction was DermTech, Inc. Common Stock, cutting an estimated $2.54M.
  • Oracle Investment Management fully exited SpringWorks Therapeutics in Q2 2023, selling an estimated $1.12M.
  • Oracle Investment Management's ten largest holdings make up 79% of its $136M portfolio in Q2 2023.
  • Oracle Investment Management opened 10 new positions and closed 8 in Q2 2023.
  • Oracle Investment Management's portfolio value rose 31% quarter-over-quarter to $136M.

Based on Oracle Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.